CNS Pharmaceuticals, Inc. (CNSP) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$4.30

From 52W high−44.64%

Volume4000.00

Market cap$6.34M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$4.30

From 52W high

−44.64%

Volume

4000.00

Market cap

$6.34M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.8x

P/E (TTM)

—

RSI (14)

41.1

MomentumView details →

1D Return

−4.62%

YTD Return

−15.62%

SummaryUpdated Jun 1, 2026

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Houston, Texas. The company went public in November 2019 and focuses exclusively on developing novel anti-cancer drug candidates for treating brain and central nervous system tumors, one of the most challenging areas in oncology. CNS Pharmaceuticals operates as a development-stage company with no commercial products yet approved for sale.

Ask drillr about CNS Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−91.75%

ROA (TTM)

−76.12%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+88.43%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+92.34%

EBITDA YoY

−7.97%

MomentumView details →

1D Return

−4.62%

YTD Return

−15.62%

1Y Return

−35.04%

RSI (14)

41.1

vs 50D SMA

−15.63%

vs 200D SMA

−2.62%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.86x

Quick Ratio

5.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.38

EPS Surprise

−58.33%

Beats (12Q)

5/12

Next Q EPS Est

−$0.27

Avg Surprise (4Q)

−42.54%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−16.70M

Op. CF (TTM)

−13.41M

Next earningsNov 18, 2026 →

Latest newsMore news →

CNS Pharmaceuticals, Inc. appointed Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin, and Amy Mahery as directors effective September 30, 2026.34d ago

Similar companies

Aprea Therapeutics, Inc.APRE Exicure, Inc.XCUR Enveric Biosciences, Inc.ENVB Nutriband Inc.NTRBW FibroBiologics, Inc. Common StockFBLG Immuron LimitedIMRN Find similar companies →

Latest newsMore news →

CNS Pharmaceuticals, Inc. appointed Faith Charles, Bettina Cockroft, Michal Fisher, Jeffrey Keyes, Rami Levin, and Amy Mahery as directors effective September 30, 2026.34d ago